Single-pill treatment proves as effective at suppressing virus as multi-pill therapy, while long-acting preventive injections ...

Three experimental injectable antiretrovirals – a novel capsid inhibitor and two next-generation integrase inhibitors – could ...

Merck said a treatment it is developing for HIV-1 met its primary endpoint in three Phase 3 trials. The biopharmaceutical company said Wednesday the results add to growing evidence for ...

It's designed to take the place of complicated, multiple drug regimens that many people with HIV need to follow. And it's ...

A large international clinical trial has unveiled a promising new option for people living with highly treatment-resistant ...

A new study published in The Lancet Microbe reports the first twice-yearly injectable HIV treatment regimen—combining lenacapavir, teropavimab, and zinlirvimab—has achieved high rates of viral ...

– Investigational Long-Acting, Twice-Yearly Treatment Regimen of Lenacapavir and Broadly Neutralizing Antibodies (bNAbs) Meets Primary Endpoint in Phase 2 Study and Gains Breakthrough Therapy ...

Nearly 20 states are moving to restrict assistance programs that help people afford HIV medications and treatment.

People infected with HIV must take antiretroviral drugs for life. But engineered antibodies appeared to suppress the virus for certain participants in recent trials in Africa and Europe A digital ...

Modern HIV treatment is one of medicine's great success stories. With today's therapies, many people living with HIV can ...

Transmission electron micrograph showing hepatitis B virus particles (colored orange). The Johns Hopkins Medicine-led ...

Women living with HIV/AIDS can now have safe and healthy pregnancies with early diagnosis, proper treatment, and consistent ...